Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025

Alnylam Pharmaceuticals (NASDAQ: ALNY ) had an active 2024, with the top highlight being the very positive results from the Phase III HELIOS-B study of Amvuttra (vutrisiran) in ATTR amyloidosis with cardiomyopathy (or ATTR-CM). Time will tell if HELIOS-B becomesAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ALNY, RHHBY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for ...